Abstract
EE343 Cost-Effectiveness Analysis of Resmetirom for the Treatment of Adults With Noncirrhotic NASH and Moderate-to-Advanced Liver Fibrosis in the US: Integrating the Dual NASH Resolution and Fibrosis Improvement Endpoints
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have